Received Mar 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE; patient received their first dose of GARDASIL 9 on April 1, 2024, and the second dose on March 24, 2025.; This spontaneous report was received from a Pharmacist and refers to a 39-year-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 01-Apr-2024, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Suspension for injection, dose number 1, 0.5 mL (lot #, expiration date, anatomical location, and route of administration date were not reported) for prophylaxis. On 24-Mar-2025, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Suspension for injection, dose number 2, 0.5 mL (lot #, expiration date, anatomical location, and route of administration date were not reported) for prophylaxis (Inappropriate schedule of product administration). Reporter asked about alternative dosing schedules for the suspect vaccine. No adverse effects were reported; no additional adverse event (AE) (no adverse event). Additional information is not expected.